Chengdu Easton Biopharmaceuticals Co., Ltd. (688513) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Chengdu Easton Biopharmaceuticals Co., Ltd.

Why is Chengdu Easton Biopharmaceuticals Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 8.13% and Operating profit at 7.15% over the last 5 years

OPERATING CASH FLOW(Y) Highest at CNY 335.41 MM
RAW MATERIAL COST(Y) Fallen by -1.58% (YoY)
DEBT-EQUITY RATIO (HY) Lowest at -48.64 %

With ROE of 7.78%, it has a fair valuation with a 3.48 Price to Book Value

Over the past year, while the stock has generated a return of 79.71%, its profits have fallen by -4.7%
At the current price, the company has a high dividend yield of 0.5

Market Beating performance in long term as well as near term

Along with generating 79.71% returns in the last 1 year, the stock has outperformed China Shanghai Composite in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Chengdu Easton Biopharmaceuticals Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Chengdu Easton Biopharmaceuticals Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Chengdu Easton Biopharmaceuticals Co., Ltd.

98.79%

0.77

59.13%

China Shanghai Composite

13.33%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

8.13%

EBIT Growth (5y)

7.15%

EBIT to Interest (avg)

85.62

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.48

Sales to Capital Employed (avg)

0.43

Tax Ratio

4.69%

Dividend Payout Ratio

31.42%

Pledged Shares

Institutional Holding

ROCE (avg)

14.76%

ROE (avg)

8.84%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.48

EV to EBIT

54.34

EV to EBITDA

35.15

EV to Capital Employed

5.84

EV to Sales

6.33

PEG Ratio

Dividend Yield

0.53%

ROCE (Latest)

10.75%

ROE (Latest)

7.78%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 335.41 MM

RAW MATERIAL COST(Y)

Fallen by -1.58% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -48.64 %

PRE-TAX PROFIT(Q)

Highest at CNY 87.56 MM

NET PROFIT(Q)

Highest at CNY 77.69 MM

EPS(Q)

Highest at CNY 0.48

-1What is not working for the Company

DEBTORS TURNOVER RATIO(HY)

Lowest at 4.58 times

Here's what is working for Chengdu Easton Biopharmaceuticals Co., Ltd.

Operating Cash Flow

Highest at CNY 335.41 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Pre-Tax Profit

Highest at CNY 87.56 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

Highest at CNY 77.69 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS

Highest at CNY 0.48

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Debt-Equity Ratio

Lowest at -48.64 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by -1.58% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Chengdu Easton Biopharmaceuticals Co., Ltd.

Debtors Turnover Ratio

Lowest at 4.58 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio